C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstructive pulmonary disease patients: A case-control study

International Journal of Medical Sciences

Volumn 10, Issue 8, 2013, Pages 938-947

  López Campos, Jose Luis ^a,b   Calero, Carmen ^a,b   Rojano, Belén ^a   López Porras, Marta ^a   Sáenz Coronilla, Javier ^a   Blanco, Ana I ^a   Sánchez López, Verónica ^a   Tobar, Daniela ^a   Montes Worboys, Ana ^a,b   Arellano, Elena ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

C reactive protein; Copd; Gene expression; Immunohistochemistry; Serum amyloid a

Indexed keywords

C REACTIVE PROTEIN; SERUM AMYLOID A;

AGED; ARTICLE; BRONCHUS; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING;

C-REACTIVE PROTEIN; COPD; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY.; SERUM AMYLOID A;

AGED; BASE SEQUENCE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN;

EID: 84879056871     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6152     Document Type: Article

References (35)

1. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011; 139: 165-73. doi:10.1378/chest.10-1252.
2. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respiratory research. 2010; 11: 63. doi:10.1186/1465-9921-11-63.
3. Liu SF, Wang CC, Chin CH, Chen YC, Lin MC. High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. Archivos de bronconeumologia. 2011; 47: 427-32. doi:10.1016/j.arbres.2011.04.011.
4. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2011; 37: 516-22. doi:10.1183/09031936.00029310.
5. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. The New England journal of medicine. 1999; 340: 448-54. doi:10.1056/NEJM199902113400607.
6. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010; 65: 930-6. doi:10.1136/thx.2009.130260.
7. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. American journal of respiratory and critical care medicine. 2002; 166: 1218-24.
8. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 1998; 46: 1377-84.
9. Paivaniemi OE, Maasilta PK, Vainikka TL, Alho HS, Karhunen PJ, Salminen US. Local C-reactive protein expression in obliterative lesions and the bronchial wall in posttransplant obliterative bronchiolitis. Mediators of inflammation. 2009; 2009: 510254. doi:10.1155/2009/510254.
10. Ramage L, Proudfoot L, Guy K. Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles. Inhalation toxicology. 2004; 16: 607-13. doi:10.1080/08958370490464599.
11. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, et al. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 935-40. doi:10.1073/pnas.1109382109.
12. Leon-Atance P, Moreno-Mata N, Gonzalez-Aragoneses F, Canizares-Carretero MA, Garcia-Jimenez MD, Genoves-Crespo M, et al. Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. Archivos de bronconeumologia. 2011; 47: 441-6. doi:10.1016/j.arbres.2011.04.004.
13. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. European journal of clinical investigation. 1996; 26: 427-35.
14. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3: 1101-8.
15. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, et al. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. The Journal of biological chemistry. 1992; 267: 3862-7.
16. Kumon Y, Suehiro T, Hashimoto K, Sipe JD. Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells. Scandinavian journal of immunology. 2001; 53: 7-12.
17. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91: 3186-90.
18. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. American journal of respiratory and critical care medicine. 2010; 181: 360-73. doi:10.1164/rccm.200905-0696OC.
19. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. Journal of immunology. 1996; 156: 4815-20.
20. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. The American journal of pathology. 2005; 166: 1265-71. doi:10.1016/S0002-9440(10)62345-0.
21. Lakota K, Resnik N, Mrak-Poljsak K, Sodin-Semrl S, Veranic P. Colocalization of serum amyloid a with microtubules in human coronary artery endothelial cells. Journal of biomedicine & biotechnology. 2011; 2011: 528276. doi:10.1155/2011/528276.
22. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011; 140: 626-33. doi:10.1378/chest.10-2948.
23. Bafadhel M, Umar I, Gupta S, Raj JV, Vara DD, Entwisle JJ, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011; 140: 634-42. doi:10.1378/chest.10-3007.
24. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. The New England journal of medicine. 2011; 365: 1567-75. doi:10.1056/NEJMoa1106955.
25. Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2006; 3: 434-9. doi:10.1513/pats.200601-006AW.
26. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. American journal of respiratory and critical care medicine. 2010; 182: 598-604. doi:10.1164/rccm.200912-1843CC.
27. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Archivos de bronconeumologia. 2012; 48: 86-98. doi:10.1016/j.arbres.2011.10.007.
28. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology today. 1994; 15: 81-8. doi:10.1016/0167-5699(94)90138-4.
29. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical chemistry. 2009; 55: 611-22. doi:10.1373/clinchem.2008.112797.
30. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Molecular and cellular biology. 1999; 19: 1720-30.
31. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61: 23-8. doi:10.1136/thx.2005.042200.
32. Wozniak K, Sleszycka J, Safianowska A, Wiechno W, Domagala-Kulawik J. Systemic inflammation in peripheral arterial disease with or without coexistent chronic obstructive pulmonary disease: analysis of selected markers. Archives of medical science: AMS. 2012; 8: 477-83. doi:10.5114/aoms.2012.29403.
33. Young RP, Hopkins RJ, Whittington CF, Hay BA, Epton MJ, Gamble GD. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PloS one. 2011; 6: e16476. doi:10.1371/journal.pone.0016476.
34. Sundar IK, Mullapudi N, Yao H, Spivack SD, Rahman I. Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics. Current opinion in pulmonary medicine. 2011; 17: 279-85. doi:10.1097/MCP.0b013e3283477533.
35. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. American journal of respiratory and critical care medicine. 2011; 184: 913-9. doi:10.1164/rccm.201103-0430OC.